

# Global Viral Vector Manufacturing Markets and Technologies Through 2022

<https://marketpublishers.com/r/GDBB0B0DEE0EN.html>

Date: October 2018

Pages: 255

Price: US\$ 1,375.00 (Single User License)

ID: GDBB0B0DEE0EN

## Abstracts

### Report Scope

The scope of this report is broad and covers various types of products available, ongoing research and development in the viral vector vaccine manufacturing market, and potential application sectors across various industries. The viral vector vaccine manufacturing market is broken down by types, application and diseases. Revenue forecasts from 2017 to 2022 are given for each product type, application and diseases with estimated valued derived from the revenue of manufacturers' total revenues.

The report also includes a discussion of the major players across each regional viral vector vaccine manufacturing market. Further, it explains the major drivers and regional dynamics of the global viral vector vaccine manufacturing market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors in the global viral vector vaccine manufacturing market.

### Report Includes

145 data tables and 57 additional tables

A detailed overview and industry analysis of global viral vector manufacturing market

Analyses of global market trends, with data from 2017, estimates for 2018, and

projections of compound annual growth rates (CAGRs) through 2023

Information on major drivers and regional dynamics of the global viral vector vaccine manufacturing market and current trends within the industry

Insight into pipeline products that are manufactured using viral vector tools and technology, and a relevant patent analysis

Company profiles of major market players including Advanced Bioscience Laboratories Inc., Boehringer Ingelheim GmbH, Brammer Bio LLC, Creative Biogene, GE Healthcare, Pfizer Inc., Sanofi SA, and Spark Therapeutics Inc.

## Contents

### **CHAPTER 1 INTRODUCTION**

Study Goals and Objectives  
Reasons for Doing This Study  
Scope of Report  
Methodology  
Geographic Breakdown  
Analyst's Credentials  
BCC Custom Research  
Related Research Reports

### **CHAPTER 2 SUMMARY AND HIGHLIGHTS**

### **CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND**

Evolution and Transition  
Market Potential  
WHO  
U.S.  
European Union  
Australia  
Japan  
India  
China  
Market Segmentation  
Segmentation by Type  
Segmentation by Application  
Segmentation by Disease  
Regional Analysis  
North America  
Europe  
Asia-Pacific  
ROW

### **CHAPTER 4 MARKET DRIVERS**

Rising Number of Clinical Trials in Viral Vectors

Growing Number of Gene Therapy Candidates  
Surging Investment in Gene-Therapy-Based R&D Activities  
Increasing Prevalence of Genetic Disorders and Chronic Diseases

## **CHAPTER 5 MARKET BREAKDOWN BY TYPE**

Overview  
Adenoviral Vectors  
Retroviral Vectors  
Lentiviral Vectors  
Adeno-associated Viral Vectors  
Cytomegalovirus  
Pox Virus  
Other Viral Vectors

## **CHAPTER 6 MARKET BREAKDOWN BY DISEASE APPLICATION**

Overview  
Human Disease Applications  
Overview  
Hepatitis  
Cancer  
Influenza  
HIV  
Tuberculosis  
Malaria  
Others  
Veterinary Disease Applications  
Avian Influenza  
Marek's Disease  
Infectious Bronchitis  
PPR Disease  
Others (Rabies, FMD, Swine Influenza, Equine Influenza, Newcastle Disease, etc.)

## **CHAPTER 7 MARKET BREAKDOWN BY APPLICATION TYPE**

Overview  
Multivalent Viral Vector Vaccines  
Multipathogen Viral Vector Vaccines

## **CHAPTER 8 MARKET BREAKDOWN BY REGION**

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

Asia-Pacific

China

India

Japan

Australia

South Korea

Rest of Asia-Pacific

Rest of the World (ROW)

Latin America

Middle East and Africa

## **CHAPTER 9 VIRAL VECTOR MANUFACTURING INDUSTRY STRUCTURE**

Viral Vector Manufacturing Supply Chain

Common Steps Followed in Small-Scale Manufacturing of Adenovirus

Step 1: Cell Lysis and Genomic DNA Breakdown

Step 2: Clarification

Step 3: Concentration

Steps 4 and 5: Anion Exchange and Gel Filtration

Step 6: Membrane Filtration

Companies Involved in Developing Lentiviral Vector Candidates

Companies Involved in Developing Adeno-associated Vector (AAV) Candidates

Manufacturer Purchasing Criteria

Innovation within the Viral Vector Vaccine Manufacturing Industry

Competitive Landscape

Expansions  
Collaborations  
Investments  
Acquisitions

## **CHAPTER 10 PATENT ANALYSIS**

U.S. Patent Analysis  
European Patent Analysis  
Japanese Patent Analysis

## **CHAPTER 11 COMPANY PROFILES**

ADVANCED BIOSCIENCE LABORATORIES, INC.  
ADVANCED BIOTHERAPEUTICS CONSULTING  
APPLIED VIROMICS  
BATAVIA BIOSCIENCES  
BENITEC BIOPHARMA  
BIOGEN IDEC (NOW BIOGEN, INC.)  
BIOVIAN  
BOEHRINGER INGELHEIM GMBH  
BRAMMER BIO  
CELL AND GENE THERAPY CATAPULT  
CEVA CORPORATE  
COBRA BIOLOGICS (SUBSIDIARY OF RECIP AB)  
CREATIVE BIOGENE  
GE HEALTHCARE  
GENEDETECT  
GENVEC INC. (SUBSIDIARY OF INTREXON CORP.)  
ID PHARMA CO. LTD.  
JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON  
LONZA  
MERCK MILLIPORE  
MILTENYI BIOTEC  
MOLMED SPA  
PARAGON BIOSERVICES INC.  
PFIZER INC.  
SANOFI  
SEMENTIS

SPARK THERAPEUTICS INC.

SYNPROMICS

VALNEVA

VECTOR BIOLABS

VIGENE BIOSCIENCES INC.

**VIROVEK**

## List Of Tables

### LIST OF TABLES

Summary Table: Global Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 1: Characteristics of Potential Viral Vaccine Vectors

Table 2: Advantages and Disadvantages of Major Viral Vectors

Table 3: Global Market Shares of Viral Vector Vaccine Manufacturing, by Type, 2016 vs. 2022

Table 4: Global Market Shares of Viral Vector Vaccine Manufacturing, by Application Type, 2016 and 2022

Table 5: Global Market Shares of Viral Vector Vaccine Manufacturing, by Disease Segment, 2016 and 2022

Table 6: Vaccine Designs and Strategies for Their Utility Against HIV

Table 7: Global Market Shares of Viral Vector Vaccine Manufacturing, by Region, 2016 and 2022

Table 8: Driver Impact Analysis for Global Viral Vector Vaccine Manufacturing Market

Table 9: List of Clinical Trials with Their Conditions and Interventions

Table 10: Distribution of Diseases Targeted by Prophylactic Gene-Based Vaccines

Table 11: Properties of Various Viral Vectors and Their Application in Gene Therapy

Table 12: Global Incidence of Chronic Diseases, 2005-2030

Table 13: Global Prevalence of Colon Cancer, by Age Group, 2016

Table 14: Global Incidence of HIV Disease, by Region, 2016

Table 15: Various Types of Viral Vectors Used in Gene Therapy and Their Advantages

Table 16: Characteristics of Key Viral Vectors

Table 17: Global Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 18: Global Adenoviral Vector Vaccine Manufacturing Market, by Region, Through 2022

Table 19: Global Retroviral Vector Vaccine Manufacturing Market, by Region, Through 2022

Table 20: Advantages and Disadvantages of Retroviral Vectors

Table 21: List of Retroviral Vector Vaccines under Development as of March 2018

Table 22: Components of HIV Provirus

Table 23: Clinical Trials Deploying Lentiviral Vectors for Modification of Hematopoietic Stem Cells by Phase

Table 24: Global Lentiviral Vector Vaccine Manufacturing Market, by Region, Through 2022

Table 25: Second- versus Third-Generation Lentiviral Systems



Table 26: Selected AAV Vectors with Their Tropisms and Receptors
Table 27: Global Adeno-associated Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 28: Global Cytomegalovirus Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 29: Human Cytomegalovirus Vaccine Candidates in Different Stages of Preclinical and Clinical Development
Table 30: Licensed Fowl Pox Viral-Vectored Veterinary Vaccines
Table 31: Global Pox Virus Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 32: Benefits and Drawbacks of HSV Viral Vectors
Table 33: Global Other Viral Vector Vaccines Manufacturing Market, by Region, Through 2022
Table 34: HSV Proposed Vaccines and Their Characteristics
Table 35: Global Viral Vector Vaccine Manufacturing Market, by Disease Segment, Through 2022
Table 36: Licensed Viral and Bacterial Vaccines for Use in Humans
Table 37: Global Viral Vector Vaccine Manufacturing Market, by Human Disease Application, Through 2022
Table 38: Global Viral Vector Manufacturing Market in Human Disease, by Region, Through 2022
Table 39: Pricing in Gavi Countries: Product-Specific Commitments
Table 40: Estimated New Cases of HAV
Table 41: Number of Death Certificates Listing HAV, HBC and HCV as a Cause of Death, 2015 and 2016
Table 42: Prevalence of HBV Infection (HBSAG) in the General Population, by WHO Region, 2015
Table 43: Leading Sites of Estimated New Cancer Cases in U.S, 2017
Table 44: Virus-Vectored Experimental Influenza Vaccines
Table 45: Some of the Delivery Vectors Evaluated in Clinical Studies for HIV Vaccines
Table 46: People Living with HIV, by Region, 2016
Table 47: Tuberculosis Viral Vector Vaccine Candidates
Table 48: Ongoing Preclinical Development and Clinical Trials on Malaria Vaccines
Table 49: Top 10 Priority Initiatives for Malaria Vaccine Development According to the Malaria Vaccine Technology Roadmap
Table 50: Ongoing Clinical Trials of Vector Vaccines against EVD, As of 2017
Table 51: EVD Cases and Death, by Country
Table 52: Zika Virus Vaccine Development and Ongoing Clinical Trials
Table 53: Licensed Viral-Vectored Veterinary Vaccines

Table 54: Global Estimates of the Growth in Demand for Meat, 2010–2030
Table 55: Global Viral Vector Vaccine Manufacturing Market, by Veterinary Disease Application, Through 2022
Table 56: Global Viral Vector Vaccine Manufacturing Market for Veterinary Disease Application, by Region, Through 2022
Table 57: Avian Influenza Vaccines
Table 58: Global Estimates of Poultry Production
Table 59: Marek's Disease Vaccines
Table 60: Grants Supporting the Development of Novel Recombinant Adenovirus-Based Vaccine Candidates for Respiratory Diseases in Chickens
Table 61: Global Viral Vector Vaccine Manufacturing Market, by Application, Through 2022
Table 62: Comparison of the Viral Vectors Discussed Based on Specific Vector Characteristics
Table 63: Global Multivalent Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 64: Global Incidence of HIV Disease, by Region, 2015 and 2016
Table 65: Global Incidence of TB, by Region, 2016
Table 66: Global Multipathogen Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 67: Overview of Multivalent/Polyvalent and Multipathogen/Multidisease Viral Vector Vaccine Candidates, by Vector
Table 68: Global Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 69: North American Viral Vector Vaccine Manufacturing Market, by Country, Through 2022
Table 70: North American Viral Vector Manufacturing Market, by Type, Through 2022
Table 71: Cancer Research Funding in the U.S., 2015 and 2016
Table 72: North American Viral Vector Manufacturing Market, by Application Type, Through 2022
Table 73: U.S. Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 74: North American Viral Vector Manufacturing Market, by Disease Segment, Through 2022
Table 75: NIH Funding for CRISPR-Related Research, 2006–2016
Table 76: North American Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
Table 77: New HIV Diagnoses in the U.S., by Age Group, 2016
Table 78: Viral Vector Vaccines in Development in U.S.
Table 79: Canadian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 80: North American Viral Vector Manufacturing Market, by Veterinary Disease

Application, Through 2022

Table 81: Confirmed Influenza Cases in Mexico, 2012–2016

Table 82: Mexican Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 83: European Viral Vector Vaccine Manufacturing Market, by Country, Through 2022

Table 84: Losses Due to HPAI Outbreaks in Domestic Birds, by Region, January 2013-January 2018

Table 85: Recent Impact of HPAI in Domestic Birds, by Region, February 2018

Table 86: German Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 87: European Viral Vector Manufacturing Market, by Type, Through 2022

Table 88: U.K. Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 89: European Viral Vector Manufacturing Market, by Application Type, Through 2022

Table 90: HIV/AIDS Statistics in the U.K., 2015

Table 91: People Living with HIV (All Ages) in France, 2000-2016

Table 92: French Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 93: Distribution of the Leading Causes of Death in Women in France, 2017

Table 94: Distribution of the Leading Causes of Death in Men in France, 2017

Table 95: European Viral Vector Manufacturing Market, by Disease Segment, Through 2022

Table 96: European Viral Vector Manufacturing Market, by Human Disease Application, Through 2022

Table 97: HPAI Outbreaks in Poultry and Wild Bird Cases in the E.U., October 2016 - July 2017

Table 98: European Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022

Table 99: Spanish Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 100: Number of People in Spain Infected with HIV, by Age, 2000–2016

Table 101: Italian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 102: Italian Poultry Meat Production, 2016

Table 103: Rest of Europe Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 104: Number of People Infected with HIV in Select Countries in the Rest of Europe Region, 2000–2016

Table 105: Asia-Pacific Viral Vector Vaccine Manufacturing Market, by Country, Through 2022

Table 106: Asia-Pacific Viral Vector Manufacturing Market, by Type, Through 2022

Table 107: Chinese Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 108: Asia-Pacific Viral Vector Manufacturing Market, by Application Type,

Through 2022

Table 109: Ongoing Preclinical and Clinical Trials of HIV/AIDS Vaccine in China

Table 110: Asia-Pacific Viral Vector Manufacturing Market, by Disease Segment, Through 2022

Table 111: Confirmed Cases of Human Infection with Avian Influenza in China, 2013 and 2016

Table 112: Asia-Pacific Viral Vector Manufacturing Market, by Human Disease Application, Through 2022

Table 113: Indian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 114: Prevalence of Tuberculosis Cases in India, 2016

Table 115: Asia-Pacific Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022

Table 116: Ongoing Clinical Trials Related to HIV Vaccines in India

Table 117: Japanese Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 118: Reported Cumulative Number of HIV Cases in Japan, 2012 and 2016

Table 119: Australian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 120: Various Viral Vaccine Vectors Used in AIDS Vaccine Development

Table 121: Number of Newly Diagnosed Cases of HIV Infection in Australia, 2012–2016

Table 122: South Korean Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 123: HPAI Outbreaks in South Korea, 2003–2017

Table 124: Vaccine Strains for Immunization of Chickens against H5N1 HPAIVS

Table 125: Distribution of Causes of Death in South Korea, 2016

Table 126: Rest of APAC Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 127: Leading Causes of Deaths in Singapore, 2014–2016

Table 128: Mortality by Sex and Cause of Death, 2016

Table 129: HIV/AIDS Statistics for Thailand, 2016

Table 130: Ongoing Clinical Trials for Preventive HIV Vaccine Candidates in Thailand

Table 131: Estimated Worldwide Rates of Skin Cancer per Capita

Table 132: Newly Diagnosed HIV Cases in the Philippines, by Age Group, 2016

Table 133: Number of Newly Diagnosed HIV Cases per Day in the Philippines, 2008–2017

Table 134: ROW Viral Vector Vaccine Manufacturing Market, by Region, Through 2022

Table 135: ROW Viral Vector Manufacturing Market, by Type, Through 2022

Table 136: Latin American Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 137: Poultry Consumption across ROW Countries, 2017

Table 138: ROW Viral Vector Manufacturing Market by Application Type Through 2022

Table 139: Top 10 Causes of Deaths in Cuba and Percentage Change from 2005 to 2016

Table 140: Middle East and African Viral Vector Vaccine Manufacturing Market, by Type, Through 2022

Table 141: ROW Viral Vector Manufacturing Market, by Disease Segment, 2017–2022

Table 142: Characteristics of the Priority Diseases Identified in the WHO R&D Blueprint, Revised, 2017

Table 143: ROW Viral Vector Manufacturing Market, by Human Disease Application, Through 2022

Table 144: ROW Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022

Table 145: Viral Vector Overview

Table 146: Related Impurities to be Eliminated, by Downstream Processing

Table 147: Viral Vector Manufacturing Suppliers

Table 148: List of Some of the Viral Vector Producers

Table 149: List of Company Expansion

Table 150: List of Collaborations

Table 151: List of Investments

Table 152: List of Acquisitions

Table 153: U.S. Viral Vector Vaccine Manufacturing Patents, 2015-May 2018

Table 154: European Viral Vector Vaccine Manufacturing Patents, 2015-May 2018

Table 155: Japanese Viral Vector Vaccine Manufacturing Patents, 2015-May 2018

Table 156: Advanced BioScience Laboratories Product Portfolio

Table 157: Advanced BioScience Laboratories Recent Developments, 2015-April 2018

Table 158: Advanced Biotherapeutics Consulting Product Portfolio

Table 159: Applied Viromics Product Portfolio

Table 160: Batavia Biosciences Product Portfolio

Table 161: Batavia Bioscience Recent Developments, 2015-April 2018

Table 162: Benitec Biopharma Product Portfolio

Table 163: Biogen Product Portfolio

Table 164: Biogen Recent Developments, 2015-April 2018

Table 165: Biovian Product Portfolio

Table 166: Boehringer Ingelheim Product Portfolio

Table 167: Brammer Bio Product Portfolio

Table 168: Brammer Bio Recent Developments, 2015-April 2018

Table 169: Cell and Gene Therapy Catapult Product Portfolio

Table 170: Cell and Gene Therapy Catapult Recent Developments, 2015 - April 2018

Table 171: Ceva Product Portfolio
Table 172: Cobra Biologics Product Portfolio
Table 173: Cobra Biologics Recent Developments, 2015 - April 2018
Table 174: Creative Biogene Product Portfolio
Table 175: GE Healthcare Product Portfolio
Table 176: GeneDetect Product Portfolio
Table 177: GenVec Product Portfolio
Table 178: ID Pharma Product Portfolio
Table 179: Janssen Product Portfolio
Table 180: Janssen Recent Developments, 2015 - April 2018
Table 181: Lonza Group Product Portfolio
Table 182: Lonza Group Recent Developments, 2015 - April 2018
Table 183: Merck Millipore Product Portfolio
Table 184: Merck Millipore Recent Developments, 2015 - April 2018
Table 185: Miltenyi Biotec Product Portfolio
Table 186: MolMed Product Portfolio
Table 187: Paragon Bioservices Product Portfolio
Table 188: Paragon Bioservices Recent Developments, 2015 - April 2018
Table 189: Pfizer Product Portfolio
Table 190: Pfizer Recent Developments, 2015 - April 2018
Table 191: Sanofi Product Portfolio
Table 192: Sementis Product Portfolio
Table 193: Spark Therapeutics Product Portfolio
Table 194: Spark Therapeutics Recent Developments, 2015 - April 2018
Table 195: Synpromics Product Portfolio
Table 196: Synpromics Recent Developments, 2015 - April 2018
Table 197: Valneva Product Portfolio
Table 198: Vector Biolabs Product Portfolio
Table 199: Vigene Biosciences Product Portfolio
Table 200: Vigene Biosciences Recent Developments, 2015 - April 2018
Table 201: Virovek Product Portfolio



## List Of Figures

### LIST OF FIGURES

Summary Figure: Global Viral Vector Vaccine Manufacturing Market, by Type, 2017–2022

Figure 1: Notable Vaccine Advancements

Figure 2: Vaccine Research Cycle

Figure 3: WHO Mandatory Steps for Vaccine Approval

Figure 4: FDA Stages of Vaccine Review and Regulation

Figure 5: EMA Stages of Vaccine Review and Regulation

Figure 6: MHLW Stages of Vaccine Review and Regulation

Figure 7: Vaccine Approval Process in India

Figure 8: Life Cycle of Virus in Cells

Figure 9: Key Properties of Viral Vector

Figure 10: Global Market Shares of Viral Vector Vaccine Manufacturing, by Type, 2016 and 2022

Figure 11: Working of an Ad-Vector Vaccine

Figure 12: Role of CMV in Immunosenesce of Humans

Figure 13: Global Market Shares of Viral Vector Vaccine Manufacturing, by Application Type, 2016 - 2022

Figure 14: Global Market Shares of Viral Vector Vaccine Manufacturing, by Disease Segment, 2016 and 2022

Figure 15: Global Market Shares of Viral Vector Vaccine Manufacturing, by Region, 2016 and 2022

Figure 16: Distribution of Diseases Targeted by Prophylactic Gene-Based Vaccines

Figure 17: Global Incidence of Chronic Diseases 2005-2030

Figure 18: Global Prevalence of Colon Cancer, by Age Group, 2016

Figure 19: Global Incidence of HIV Disease, by Region, 2016

Figure 20: Structure of Third-Generation Lentiviral Vectors

Figure 21: Prevalence of HBV Infection (HBSAG) in the General Population, by WHO Region, 2015

Figure 22: People Living with HIV, by Region, 2016

Figure 23: EVD Cases and Death, by Country

Figure 24: Global Estimates of the Growth in Demand for Meat, 2010-2030

Figure 25: Global Shares of Demand for Meat, 2010 and 2030

Figure 26: Global Estimates of Poultry Production

Figure 27: Schematic Overview of Multipathogen/Multidisease and Multivalent/Polyvalent Viral Vector Vaccines

- Figure 28: Global Incidence of HIV Disease, by Region, 2015 and 2016
- Figure 29: Comparative Analysis of Regional Market Shares, 2016 vs. 2022
- Figure 30: New HIV Diagnoses in the U.S., by Age Group, 2016
- Figure 31: Confirmed Influenza Cases in Mexico, 2012–2016
- Figure 32: Losses Due to HPAI Outbreaks in Domestic Birds, by Region, January 2013–January 2018
- Figure 33: People Living with HIV (All Ages) in France, 2000–2016
- Figure 34: Distribution of the Leading Causes of Death in Women in France, 2017
- Figure 35: Distribution of the Leading Causes of Death in Men in France, 2017
- Figure 36: Number of People in Spain Infected with HIV, by Age, 2000–2016
- Figure 37: Italian Poultry Meat Production, 2016
- Figure 38: Number of People Infected with HIV in Select Countries in the Rest of Europe Region, 2000–2016
- Figure 39: Confirmed Human Infection with Avian Influenza in China, 2013 and 2016
- Figure 40: Reported Cumulative Number of HIV Cases in Japan, 2012 and 2016
- Figure 41: Number of Newly Diagnosed Cases of HIV Infection in Australia, 2012–2016
- Figure 42: Distribution of Causes of Death in South Korea, 2016
- Figure 43: Estimated Worldwide Rates of Skin Cancer per Capita
- Figure 44: Newly Diagnosed HIV Cases in the Philippines, by Age Group, 2016
- Figure 45: Number of Newly Diagnosed HIV Cases per Day in the Philippines, 2008–2017
- Figure 46: Poultry Consumption Across ROW Countries, 2017
- Figure 47: Features of Vectors
- Figure 48: Key Properties of Viral Vectors
- Figure 49: Common Viral-Vector Manufacturing Process
- Figure 50: Viral Vector Manufacturing Process
- Figure 51: Adenovirus Manufacturing Process
- Figure 52: Viral-Vector Vaccine Manufacturing Industry
- Figure 53: Level of Impact of Manufacturer Purchasing Criteria, 2018–2022
- Figure 54: Shares of Competitive Landscape, 2015–2018



## I would like to order

Product name: Global Viral Vector Manufacturing Markets and Technologies Through 2022

Product link: <https://marketpublishers.com/r/GDBB0B0DEE0EN.html>

Price: US\$ 1,375.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDBB0B0DEE0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970